Cargando…

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia

Background: Tumor-induced osteomalacia (TIO) is a rare cause of FGF23-mediated hypophosphatemia in which mesenchymal tumors produce ectopic FGF23, leading to renal phosphate wasting, decreased 1,25-dihydroxy-vitamin D and hypophosphatemia. Clinical features include muscle weakness, fractures and bon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gafni, Rachel Ilana, Spector, Ellen J, Hartley, Iris Ruth, Redd, Bernadette, Mitnik, Gabriela Lopez, Collins, Michael T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209752/ http://dx.doi.org/10.1210/jendso/bvaa046.960

Ejemplares similares

MON-502 It's Not Always Osteoporosis: FGF-23 Induced Osteomalacia
por: Bello Segura, Manuel, et al.
Publicado: (2019)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

MON-364 Severe Postoperative Encephalopathy in a Patient with Oncogenic Osteomalacia and Neurofibromatosis Type 1
por: Sarkar, Sauradeep, et al.
Publicado: (2020)

Diagnostic Dilemma of Elevated FGF23 in a Patient With Osteomalacia: A Case Report
por: Bulut, Aysegul, et al.
Publicado: (2021)

SAT-385 A Normal FGF23 Does Not Preclude Tumor Induced Osteomalacia (TIO)
por: Nandam, Neeharika, et al.
Publicado: (2020)

SUN-526 Prevalence of Hyperparathyroidism in X-Linked Hypophosphatemia
por: DeLacey, Sean, et al.
Publicado: (2019)

SUN-514 Severe Hypophosphatemia and Worsening Secondary Hyperparathyroidism Following Treatment with Denosumab
por: Adepoju, Yewande, et al.
Publicado: (2019)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

SUN-336 Obesity and Impaired Glucose Metabolism in Adult Patients with X-Linked Hypophosphatemia
por: Lecoq, Anne-Lise, et al.
Publicado: (2020)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

FRI674 Association Between Metabolic Syndrome And The Presence Of Enthesophytes On Musculoskeletal Ultrasound Compared To Joint X-ray
por: Brown, Sean, et al.
Publicado: (2023)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

SUN-345 Use of Anti-FGF23 Monoclonal Antibody in the Treatment of Children and Adolescents with X-Linked Hypophosphatemic Rickets
por: Cassinelli, Hamilton Raul, et al.
Publicado: (2020)

SUN-LB093 Change in Bone Mineral Density over One Year Was Not Associated with FGF-23 in Patients New to Dialysis
por: Roy, Neil, et al.
Publicado: (2019)

SUN-527 Clinical Experts' Views Regarding the Impact of X-Linked Hypophosphatemia on Health-Related Quality of Life (HRQL)
por: Lloyd, Andrew, et al.
Publicado: (2019)

OR23-03 Sustained Normalization Of Mineral Homeostasis In Autosomal Dominant Hypocalcemia Type 1: Results From A Phase 2 Study Over 18 Months Of Encaleret (CLTX-305) Treatment (NCT04581629)
por: Ilana Gafni, Rachel, et al.
Publicado: (2023)

SUN-359 Antenatal Oral Iron Supplementation, FGF23 and Bone Metabolism in Kenyan Women and Their Offspring: A Randomised Controlled Trial
por: Braithwaite, Vickie S, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

SAT-364 Brown Tumor of the Mandible in Severe Uncontrolled Primary Hyperparathyroidism
por: Gupta, Suruchi K, et al.
Publicado: (2020)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

Intravenous Iron Induced Severe Hypophosphatemia
por: Guo, Rong R, et al.
Publicado: (2021)

ODP071 A Fit of Hypophosphatemia
por: Naha, Sowjanya, et al.
Publicado: (2022)

SAT-362 A Bone to Pick with FGF23
por: Soliman, Peter, et al.
Publicado: (2020)

ODP085 Denosumab Induced Severe Hypophosphatemia
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022)

Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Dahir, Kathryn, et al.
Publicado: (2021)

OR13-3 Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Japalaghi, Omid K, et al.
Publicado: (2022)

Severe Osteomalacia and Fractures Secondary to Vitamin D Deficiency
por: Mathew, Justin, et al.
Publicado: (2021)

MON-490 Iatrogenic Hypophosphatemia Presenting as Low Bone Mass
por: Sharma, Shiksha, et al.
Publicado: (2019)

A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX-305) in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
por: Gafni, Rachel Ilana, et al.
Publicado: (2021)

MON-501 A Hemangioma Causing Tumor Induced Osteomalacia
por: Chinnakotla, Venkata Sai Bhavana, et al.
Publicado: (2019)

THU464 An Uncommon Case Of Adult-Onset Hypophosphatemic Osteomalacia
por: Lockhart, Paola M, et al.
Publicado: (2023)

MON-343 The Mystery of Recurrent PTH-Independent Hypercalcemia with Severe Hypophosphatemia
por: Shaikh, Bilal, et al.
Publicado: (2020)

The Effects of Encaleret (CLTX-305) on Mineral Physiology in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrate Proof-of-Concept: Early Results From an Ongoing Phase 2b, Open-Label, Dose-Ranging Study
por: Gafni, Rachel Ilana, et al.
Publicado: (2021)

MON-344 Uncommon Etiology of Hypophosphatemia and Secondary Hyperparathyroidism: Ferric Carboxymaltose Infusion
por: Sever, Sakine
Publicado: (2020)

Hip Geometry Variation in Homozygous Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficient Patients
por: Theng, Elizabeth H, et al.
Publicado: (2021)

SAT-337 Ga-DOTATATE and Tumor Induced Osteomalacia: Finding the Culprit Lesion
por: Berman, Jessica, et al.
Publicado: (2020)

MON-352 When Osteoporosis Does Not Make Sense: Tumor-Induced Osteomalacia
por: Techathaveewat, Pawarid, et al.
Publicado: (2020)

Tumor Induced Osteomalacia - Long Term Medical Treatment When Surgery Is Risky
por: Levy, Shiri, et al.
Publicado: (2021)

Successful Medical Management of a Non-Localising Case of Tumour-Induced Osteomalacia
por: Shan Hoong, Caroline Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_82aci2pgcq5ison76g7fbf096o